Table 3
Steroid dosage and refractive error
| Author, year | Subjects (total) | Modality: dose* | Refraction before treatment | SE before treatment | Refraction after treatment | SE after treatment | Age (months) | Following (months) |
|---|---|---|---|---|---|---|---|---|
| *Dosages for combination steroid injections are listed as triamcinolone (mg) followed by betamethasone (mg) unless otherwise specified. | ||||||||
| SE, spherical equivalent; Top = topical, IL = intralesional. Values in bold are for the unaffected eye, when available. | ||||||||
| Elsas15 1994 | 5 (5) | Top: clobetasol 0.05% | +2.00+3.00×140 | +3.50 | +5.00+1.00×20 | +5.50 | 14 weeks | 60 |
| +2.00 sph | +2.00 | +0.75 sph | +0.75 | |||||
| Top: clobetasol 0.05% | −1.50+1.00×45 | −1.00 | +1.50+0.50×120 | +1.75 | 3 | 37 | ||
| +2.00+0.50×135 | +2.25 | 20/30 | ||||||
| Top: clobetasol 0.05% | +1.00 sph | +1.00 | −5.75+3.00×55 | −4.25 | 11 weeks | 38 | ||
| +1.00 sph | +0.75+0.75×45 | +1.13 | ||||||
| Top: clobetasol 0.05%, pred drops | +1.00 sph | +1.00 | −10.00 | −10.00 | 9 weeks | 20 | ||
| +1.00 sph | +1.00 | −1.00 sph | −1.00 | |||||
| Top: clobetasol 0.05%, pred drops | −1.50+1.00×135 | −1.00 | −1.50+1.50×145 | −0.75 | 11 weeks | 8 | ||
| −1.00+0.50×90 | −0.75 | +1.00 sph | +1.00 | |||||
| Kushner33 1982 | 5 (10) | IL:l 12 mg/80 mg, 9 mg/6 mg | +1.75+1.00×180 | +2.25 | +1.75 sph | +1.75 | 4 | 7 |
| +1.00 sph | +1.00 | +1.50 sph | +1.50 | |||||
| IL: 40 mg/6 mg ×2 | Plano+3.50×20 | +1.75 | −1.50+1.50×80 | −0.75 | 3 | 13 | ||
| +2.50+0.50×135 | +2.75 | Plano | Plano | |||||
| IL: 40 mg/6 mg ×2 | +4.00+3.00×10 | +5.50 | +0.50+1.00×35 | +1.00 | 2 | 13 | ||
| +3.00 sph | +3.00 | +0.50 sph | +0.50 | |||||
| IL: 40 mg/6 mg ×2 | +1.00+2.50×80 | +2.25 | +0.50+0.75×80 | +0.87 | 10 | 6 | ||
| +0.50 sph | +0.50 | +0.50 sph | +0.50 | |||||
| IL: 6 mg betamethasone | +1.50 sph | +1.50 | +1.50 sph | +1.50 | 3 | 48 | ||
| +1.50 sph | +1.50 | +1.50 sph | +1.50 | |||||
| Morrell19 1991 | 13 (15) | IL: 20–40 mg/4 mg, up to 4× | −1.00+3.00×110 | +0.50 | +1.50 sph | +1.50 | 6 | 6 |
| +3.50+1.50×155 | +4.25 | +2.00 sph | +2.00 | 15 | 46 | |||
| −0.25+0.75×180 | +0.13 | −0.75+0.50×180 | −0.50 | 3 | 18 | |||
| −0.50+2.00×180 | +0.50 | Plano+1.50×180 | +0.75 | 3 | 12 | |||
| −2.00+2.50×120 | −0.75 | −0.75+2.25×120 | +0.38 | 12 | 21 | |||
| +1.50+2.50×125 | +2.75 | +0.75 sph | +0.75 | 5 | 24 | |||
| −2.00+3.25×120 | −0.38 | −2.00+3.25×117 | −0.38 | 14 years | 31 | |||
| +1.50+2.50×125 | +2.75 | +1.25+0.75×175 | +1.63 | 5 | 10 | |||
| +0.50+0.75×120 | +0.88 | +0.75 sph | +0.75 | 6 | 13 | |||
| +0.25+0.75×80 | +0.63 | Plano+0.25×80 | +0.13 | 6 | 10 | |||
| +5.00+2.00×90 | +6.00 | +3.63 | 16 | 19 | ||||
| +1.50+3.00×90 | +3.00 | +2.00+1.00×90 | +2.50 | 5 | 6 | |||
| +0.50+1.50×90 | +1.25 | +0.50+0.50×90 | +0.75 | 6 | 13 | |||
| Motwani32 1995 | 5 (23) | IL: 40 mg/6 mg once | +2.00+1.00×90 | +2.50 | +1.50 sph | +1.50 | 4 | 49 |
| +2.25+0.25×90 | +2.38 | +1.00 sph | +1.00 | |||||
| +2.50+1.50×90 | +3.25 | +0.75+1.25×90 | +1.38 | 3 | 40 | |||
| +3.00+0.50×180 | +3.25 | +0.50+0.50×90 | +0.75 | |||||
| −2.75+5.50×10 | 0.00 | −3.75+3.00×10 | −2.25 | 1.5 | 65 | |||
| +1.00+1.75×20 | +1.88 | −0.50+0.75×160 | −0.13 | |||||
| +0.75+0.50×90 | +1.00 | +1.00+1.00×90 | +1.50 | 2 | 32 | |||
| +0.75 sph | +0.75 | +2.00 sph | +2.00 | |||||
| +1.00+5.00×135 | +3.50 | +1.50+2.00×135 | +2.50 | 9 | 78 | |||
| +2.50 sph | +2.50 | |||||||
